JP2017513892A5 - - Google Patents

Download PDF

Info

Publication number
JP2017513892A5
JP2017513892A5 JP2016564087A JP2016564087A JP2017513892A5 JP 2017513892 A5 JP2017513892 A5 JP 2017513892A5 JP 2016564087 A JP2016564087 A JP 2016564087A JP 2016564087 A JP2016564087 A JP 2016564087A JP 2017513892 A5 JP2017513892 A5 JP 2017513892A5
Authority
JP
Japan
Prior art keywords
methyl
hydroxy
methylsulfonyl
propanamide
dihydroisoxazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016564087A
Other languages
English (en)
Japanese (ja)
Other versions
JP6514716B2 (ja
JP2017513892A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/027009 external-priority patent/WO2015164458A1/en
Publication of JP2017513892A publication Critical patent/JP2017513892A/ja
Publication of JP2017513892A5 publication Critical patent/JP2017513892A5/ja
Application granted granted Critical
Publication of JP6514716B2 publication Critical patent/JP6514716B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016564087A 2014-04-22 2015-04-22 LpxC阻害剤としてのイソオキサゾリンヒドロキサム酸誘導体 Expired - Fee Related JP6514716B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461982467P 2014-04-22 2014-04-22
US61/982,467 2014-04-22
PCT/US2015/027009 WO2015164458A1 (en) 2014-04-22 2015-04-22 Isoxazoline hydroxamic acid derivatives as lpxc inhibitors

Publications (3)

Publication Number Publication Date
JP2017513892A JP2017513892A (ja) 2017-06-01
JP2017513892A5 true JP2017513892A5 (enExample) 2018-05-24
JP6514716B2 JP6514716B2 (ja) 2019-05-15

Family

ID=53059459

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016564087A Expired - Fee Related JP6514716B2 (ja) 2014-04-22 2015-04-22 LpxC阻害剤としてのイソオキサゾリンヒドロキサム酸誘導体

Country Status (6)

Country Link
US (2) US9637482B2 (enExample)
EP (1) EP3134401B1 (enExample)
JP (1) JP6514716B2 (enExample)
CN (1) CN106573924B (enExample)
ES (1) ES2687393T3 (enExample)
WO (1) WO2015164458A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019501896A (ja) * 2015-12-08 2019-01-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited 抗菌化合物としての置換ベンザジノン
PL3468957T3 (pl) * 2016-06-14 2021-01-25 Novartis Ag Krystaliczna postać (r)-4-(5-(cyklopropyloetynylo)izoksa-zol-3- ilo)- n-hydroksy-2-metylo-2-(metylosulfonylo)butano-amidu jako środek przeciwbakteryjny
MX379690B (es) * 2016-09-28 2025-03-11 Dong A St Co Ltd Derivados de tetrahidropiridina y su uso como agentes antibacterianos
SG11202105199QA (en) * 2018-11-21 2021-06-29 Taisho Pharmaceutical Co Ltd Novel imidazole derivative
WO2020142764A1 (en) * 2019-01-06 2020-07-09 Psomagen Inc. Htra inhibitors and caga inhibitors and use thereof
CN119816496A (zh) * 2022-09-28 2025-04-11 浙江海正药业股份有限公司 芳香乙炔类衍生物及其制备方法和用途
WO2024153173A1 (zh) * 2023-01-19 2024-07-25 浙江海正药业股份有限公司 芳香乙炔类衍生物及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9408174A (pt) * 1993-11-26 1997-05-27 Pfizer Compostos isoxazolina como agentes antiinflamatórios
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7125870B2 (en) 2002-11-06 2006-10-24 Bristol-Myers Squibb Company Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme
ES2552247T3 (es) 2003-01-08 2015-11-26 The University Of Washington Agentes antibacterianos
JP5524215B2 (ja) 2008-09-19 2014-06-18 ファイザー・インク 抗菌剤として有用なヒドロキサム酸誘導体
CA2774250C (en) 2009-10-13 2013-12-17 Pfizer Inc. C-linked hydroxamic acid derivatives useful as antibacterial agents
SI2512474T1 (sl) 2009-12-16 2014-12-31 Pfizer Inc. N-vezani derivati hidroksamske kisline, uporabni kot protibakterijska sredstva
WO2012120397A1 (en) 2011-03-07 2012-09-13 Pfizer Inc. Fluoro-pyridinone derivatives useful as antibacterial agents
JP2014510132A (ja) * 2011-04-08 2014-04-24 ファイザー・インク 抗菌剤として有用なイソオキサゾール誘導体
KR20120137094A (ko) * 2011-06-10 2012-12-20 현대자동차주식회사 차량용 소음기
WO2014160649A1 (en) 2013-03-29 2014-10-02 Novartis Ag Hydroxamic acid derivatives as lpxc inhibitors for the treatment of bacterial infections

Similar Documents

Publication Publication Date Title
JP2017513892A5 (enExample)
HRP20192009T1 (hr) Spojevi izoksazol hidroksamske kiseline kao inhibitori lpxc-a
ES2535244T3 (es) Compuestos heterocíclicos adecuados para el tratamiento de dislipidemia
RU2016117941A (ru) Фениколовые противобактериальные средства
JP2012502946A5 (enExample)
RU2019121871A (ru) Новые производные фенилпропионовой кислоты и их применение
JP2020502111A5 (enExample)
IL264982B (en) Hetero(aryl)cyclopropylamine compounds as lsd1 inhibitors
JP2013521286A5 (enExample)
JP2007525516A5 (enExample)
HRP20161011T1 (hr) Aril dihidropiridinoni i piperidinoni kao inhibitori mgat2
HRP20170422T1 (hr) 3-(2-aril-cikloalkenilmetil)-oksazolidin-2-on derivati kao inhibitori transportnog proteina estera kolesterola (cetp)
JP2015508749A5 (enExample)
JP2010516715A5 (enExample)
JP2016535758A5 (enExample)
JP2017511329A5 (enExample)
IL273000B2 (en) Compounds that inhibit lysophosphatidic acid receptor 1 (lpar1)
JP2015536974A5 (enExample)
PE20220711A1 (es) Derivados de 2-isoindol-1,3,4-oxadiazol utiles como inhibidores de la histona desacetilasa 6 (hdac6)
HRP20190668T1 (hr) Tetrazolonom supstituirani dihidropiridinonski mgat2 inhibitori
JP2017505293A5 (enExample)
RU2012142171A (ru) Ингибиторы катехол-о-метилтрансферазы и их применение в лечении психических расстройств
RU2015116540A (ru) Замещенные соединения спиропиперидинила, применяемые в качестве агонистов gpr120
JP2016516805A5 (enExample)
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1